Evidence map›Paper›PMID 38581593›Full record

ArticleEndocrine2024

Adrenal tumors in patients with neuroendocrine neoplasms.

Henrik Falhammar, Adam Stenman, C Christofer Juhlin, Anna Kistner

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Perspectives on Adrenal Tumor Surgery.Medicina (Kaunas, Lithuania) · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Henrik FalhammarDepartment of Endocrinology, Karolinska University Hospital, 171 77, Stockholm, Sweden. henrik.falhammar@ki.se.ORCID 0000-0002-5622-6987
Adam StenmanDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 76, Stockholm, Sweden.ORCID 0000-0003-3248-7629
C Christofer JuhlinDepartment of Oncology-Pathology, Karolinska Institutet, 171 76, Stockholm, Sweden.ORCID 0000-0002-5945-9081
Anna KistnerDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 76, Stockholm, Sweden.ORCID 0000-0002-7942-3211
Karolinska University Hospital · SE

Funding

Magnus Bergvalls Stiftelse 2022-047
6 · The paper itself

Abstract

purposeTo study the prevalence of primary adrenal tumors and adrenal metastases in patients with neuroendocrine neoplasms (NENs) and describe these in detail. NENs can be further divided into neuroendocrine tumor (NET) and neuroendocrine carcinoma (NEC).

methodsA review of medical files was conducted for all patients who underwent a

resultsIn total,

conclusionAdrenal primary tumors and adrenal metastases are infrequent occurrences in patients with NEN. Most cases involved the presence of NEN metastasis upon the initial discovery of adrenal tumors. The overall prognosis was found to be favorable.

Indexed as

AdrenalectomyAdrenal Gland NeoplasmsNeuroendocrine TumorsPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overCarcinoma, NeuroendocrineFemaleHumansMaleMiddle AgedPrevalenceRetrospective Studies68Gallium-DOTATOC-PET/CTAdrenalectomyAdrenal metastasisAdrenal tumorNeuroendocrine cancerNeuroendocrine tumor

Identifiers

PMID38581593
PMCPMC11246291
OpenAlexW4394011161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.